Seizure Prophylaxis for Traumatic Head Bleeds
Routine seizure prophylaxis is generally not recommended for patients with traumatic intracranial hemorrhage, as the evidence shows no significant benefit in preventing early or late seizures, with potential harm from adverse effects and worse neurological outcomes.
Evidence-Based Recommendation
The 2018 European guideline on severe TBI management explicitly states: "We do not suggest using antiepileptic drugs for primary prevention to reduce the incidence of post-traumatic seizures (early and delayed)" (Grade 2-, Strong Agreement) 1. This recommendation is reinforced by the 2024 Neurocritical Care Society guidelines, which suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence) 2.
Key Evidence Against Routine Prophylaxis
The guideline analysis reviewed 11 clinical trials (2,784 patients total) comparing various antiepileptic drugs versus placebo or no treatment 1. The findings were striking:
- No significant effect on preventing early or delayed post-traumatic seizures
- Increased side effects with phenytoin use
- Worsening neurological outcomes associated with antiepileptic drug use
- The overall incidence of early clinical seizures is only 2.2% within 7 days for all TBI severities, though it rises to 11.9% in the first year for severe TBI 1
A 2018 prospective observational study comparing 522 patients (272 with prophylaxis vs. 250 without) found no significant difference in early seizure rates: 3.7% with prophylaxis versus 2.8% without (p=0.573) 3. Even in high-risk subgroups like decompressive craniectomy patients, the benefit was not demonstrated 3.
When to Consider Prophylaxis (Selective Use)
While routine prophylaxis is not recommended, consider selective use in specific high-risk scenarios 1:
High-Risk Features:
- Brain contusion
- Acute subdural hematoma
- Skull fracture
- Loss of consciousness or amnesia >24 hours
- Age >65 years
- Craniectomy (identified as a possible risk factor)
- Past history of epilepsy
If Prophylaxis is Used:
Drug Selection: Levetiracetam should be preferred over phenytoin/fosphenytoin due to higher tolerance and fewer adverse effects 1, 2. The 2024 NCS guidelines support this with a weak recommendation based on very low quality evidence 2.
Duration: Limit to ≤7 days maximum 2. The evidence shows:
- No benefit for longer durations in preventing late seizures
- Worse cognitive outcomes and increased adverse events with protracted use 2
- Quality-adjusted life-years are increased with shorter duration 4
Clinical Algorithm
Assess TBI severity and imaging findings
- Document GCS score
- Identify specific hemorrhage patterns (subdural, subarachnoid, contusion, etc.)
Stratify seizure risk:
- Low risk (isolated small hemorrhage, GCS 13-15, no risk factors): No prophylaxis
- High risk (multiple risk factors listed above): Consider prophylaxis
If prophylaxis chosen:
- Drug: Levetiracetam (NOT phenytoin)
- Duration: Maximum 7 days
- Monitoring: Daily clinical assessment for seizures
- Documentation: Clear stop date to prevent inappropriate continuation
Do NOT use prophylaxis for:
- Prevention of late seizures (>7 days)
- Routine mild-moderate TBI without risk factors
Important Caveats
Common Pitfall: The 2024 meta-analysis on mild-moderate TBI showed only a 0.6% absolute risk reduction with prophylaxis, requiring treatment of 167 patients to prevent one seizure 5. This minimal benefit must be weighed against medication risks and the danger of inappropriate continuation beyond 7 days.
Practice Reality: A 2020 study found only 8% of patients received recommended prophylaxis, with no increase after guideline publication 6. This suggests either poor guideline adherence or clinical recognition that routine prophylaxis lacks compelling benefit.
Mortality Consideration: Studies consistently show higher mortality in patients receiving prophylaxis, but this reflects confounding by indication—more severely injured patients receive prophylaxis 7. The prophylaxis itself does not cause increased mortality when adjusted for injury severity.
The evidence strongly supports a selective, time-limited approach rather than routine prophylaxis for all traumatic intracranial hemorrhages 1, 2, 3.